Resources

This page lists the medical devices and human tissue products private health insurers must pay benefits for to the patients who have appropriate insurance policies. The latest version of the Prescribed List is effective from 1 March 2025.

This document provides a high-level summary of stakeholder feedback received in response to Consultation Paper 9 – CIED and the cost of technical support services.

We have developed a Prescribed List Post-listing Review Framework that is used to guide the post-listing review process as part of the Prescribed List Reforms.

The interim evaluation report covers the period from May 2021 to June 2024 and reports on whether the reforms being implemented and achieving the expected outcomes.

This evaluation focuses on the Prostheses List reforms, which are running from 1 July 2021 to 30 June 2025. Evaluation of these reforms will determine whether the reform program is being implemented as intended.

This report provides an analysis of stakeholder feedback received in response to the Consultation Paper on the proposed Compliance, Assurance and Information sharing measures for the Prescribed List (PL).

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: Prescribed List (PL) gifts, benefits and discounts reporting requirements.

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: alignment of amount charged for supply of a device with corresponding PL benefit.

This report is a review of surgical guides and biomodels currently listed on the Prostheses List.

These documents contain advice on the Prescribed List (PL) adjusted benefits, resulting from the public benchmarking undertaken by the Independent Health and Aged Care Pricing Authority (IHACPA). The documents outline the November 2023 PL benefits, and the adjusted benefits effective 1 July 2024.

This cost recovery implementation statement describes how the Department of Health and Aged Care recovers the costs of administering the Prescribed List of Benefits for Medical Devices and Human Tissue Products.

Terms of reference for the Medical Devices and Human Tissue Advisory Committee.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a - Listing Criteria.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6a – Listing Criteria.

This report provides an analysis of stakeholder feedback received in response to the Prostheses List Reform Consultation Paper 6b Cost Recovery Arrangements.

The below document outlines Prescribed List compliance obligations for relevant stakeholders and the Australian Government.

The below report provides analysis of stakeholder feedback to the proposed Prostheses List Compliance Strategy. The submission period for responses was between 14 September and 21 October 2022.

The below data documents detail cardiac implantable electronic devices (CIEDs) that will have their Prostheses List (PL) benefits reduced by 40% of the gap on 1 July 2023.

This report details supplementary advice on bundling arrangements for General Use Items on the Prostheses List.

This report provides an analysis of stakeholder feedback requested through webinars and written responses to the Prostheses List reforms consultation paper 4 (a) and 4 (b).

This report outlines the pre-listing assessment framework and governance structure for the Prostheses List. It also addresses Ernst & Young, and Adelaide Health Technology Assessment options and recommendations.

This report provides a framework and proposes options for governance that would align the Prostheses List processes with those of other health technology assessment processes within the Government. It was developed by Adelaide Health Technology Assessment, under the Prostheses List Reform program.

This review provides options and recommendations for the future governance of the Prostheses List. It was developed by Ernst & Young under the Department’s Prostheses List Reform program.